Medivir AB
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Sweden, the Nordic region, rest of Europe, and internationally. The company offers Xerclear for the treatment of labial herpes under the Zoviduo name; and Olysio to treat hepatitis C. It also develops Remetinostat, a histone deacetylase (HDAC) inhibitor that has completed Phas… Read more
Medivir AB (MVIR) - Net Assets
Latest net assets as of : Skr- SEK
Based on the latest financial reports, Medivir AB (MVIR) has net assets worth Skr- SEK as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr-) and total liabilities (Skr-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Medivir AB - Net Assets Trend (None–None)
This chart illustrates how Medivir AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Medivir AB (None–None)
The table below shows the annual net assets of Medivir AB from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to Medivir AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Medivir AB Competitors by Market Cap
The table below lists competitors of Medivir AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
World Flex PCL
BK:WFX
|
$4.50 Million |
|
POD POINT GROUP LS -0001
F:6EO
|
$4.50 Million |
|
ASHFORD HOSPIT.TRUST
F:AHD
|
$4.50 Million |
|
Cheetah Holdings Bhd
KLSE:7209
|
$4.50 Million |
|
Dominion Water Reserves Corp
PINK:DOMWF
|
$4.49 Million |
|
Kothari Products Limited
NSE:KOTHARIPRO
|
$4.49 Million |
|
Mixed Martial Arts Group Limited
NYSE MKT:MMA
|
$4.49 Million |
|
PMHS
PINK:PMHS
|
$4.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medivir AB's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Medivir AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Medivir AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares Medivir AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medivir AB (MVIR) | Skr- | N/A | N/A | $4.50 Million |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |